Position in NVO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$453,991
+$78,406 QoQ
Shares Held
9,470
-7.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.80%
of 13F equity value
Holder Rank
#744
of 1,348 holders
Holding Since
Jun 2020
19 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026WFA of San Diego, LLC holds $2,758,444 across 6 Drug Manufacturers - General names. NVO ranks #4 (16.5% of the industry book) .
All Filings in NVO
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $453,991 | 9,470 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $375,585 | 10,220 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $525,081 | 10,320 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $571,824 | 10,305 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $711,251 | 10,305 | Shares | Sole | 2025-08-15 | |
| 2024-09-30 | $1,228,207 | 10,315 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $1,479,500 | 10,365 | Shares | Sole | 2024-08-14 | |
| 2023-09-30 | $977,605 | 10,750 | Shares | Sole | 2023-11-02 | |
| 2023-06-30 | $890,065 | 5,500 | Shares | Sole | 2023-08-10 | |
| 2022-12-31 | $900,011 | 6,650 | Shares | Sole | 2023-01-31 | |
| 2022-09-30 | $687,447 | 6,900 | Shares | Sole | 2022-10-18 | |
| 2022-06-30 | $768,867 | 6,900 | Shares | Sole | 2022-07-28 | |
| 2022-03-31 | $766,245 | 6,900 | Shares | Sole | 2022-04-25 | |
| 2021-12-31 | $780,640 | 6,970 | Shares | Sole | 2022-02-07 | |
| 2021-09-30 | $669,189 | 6,970 | Shares | Sole | 2021-10-25 | |
| 2021-06-30 | $583,876 | 6,970 | Shares | Sole | 2021-08-11 | |
| 2021-03-31 | $469,917 | 6,970 | Shares | Sole | 2021-05-14 | |
| 2020-09-30 | $483,927 | 6,970 | Shares | Sole | 2020-11-06 | |
| 2020-06-30 | $456,395 | 6,970 | Shares | Sole | 2020-08-27 | |
| No filing history on record for this holder in this stock. | ||||||